DCB in PCI: Adjunctive Therapy or Standard of Care?
Published: 14 February 2022
Part 1 | Session 2 Episode 2: The benefits vs DES and PTX vs Limus
Part 2 | Session 1 Episode 1: DCB: Role of Predilatation and dissection assessment
Part 2 | Session 2 Episode 2: DCB: Acute and long-term results after DCB-alone PCI
Part 2 | Session 3 Episode 3: Risk of abrupt closure and use of adjunctive technologies
Learn more about the origins and science behind the DCB technology, the important clinical data supporting DCB use in the coronary arteries, existing and emerging treatment indications through videos, interviews and panel discussions with renowned faculty from highly ranked institutions.
Key Learning Objectives
- To discuss the origins and science behind the DCB technology, its current and potential areas of application in various clinical scenarios, and emphasize the benefits of DCB technology vs DES and Paclitaxel vs Limus.
- To emphasize the importance of vessel preparation, algorithms of optimal therapy delivery and criteria used for immediate results evaluation.
- To highlight the DCB Clinical Program, understanding the clinical benefits and safety of paclitaxel DCBs, and its relevance to your daily practice
- Interventional Cardiologists
- General Cardiologists
- Allied Healthcare Professionals
More from this programme
Science of DCB
DCB: Role of Predilatation and dissection assessment
Dr Bruno Scheller studied medicine at the University of Saarland, Germany, from 1988 til 1994. Since 1994 he has been working as a physician at the clinic for internal medicine III,, University Hospital of Saarland, Homburg/Saar, Germany, where he is a consultant for internal medicine, cardiology, and intensive care. He is a full professor for Clinical and Experimental Interventional Cardiology at the Medical School of the University.
Veterinary Pathologist, Fellow in Comparative Medicine, specializing in the field of medical device pathology
Dr Mylotte graduated from RCSI Medical School in 2001, obtained membership of the Royal College of Physicians in Ireland in 2004, and completed the Irish Cardiology Specialist Training Scheme. He and was conferred with a Doctor of Medicine (MD) thesis in 2010 by the Royal College of Surgeons in Ireland and has also undertaken a PhD thesis. N the subject of Transcatheter Aortic Valve Implantation (TAVI) at the world renowned ThoraxCentre in Rotterdam, The Netherlands.
Dr Mylotte specializes in general cardiology, and has subspecialty interests in the assessment, diagnosis and treatment of ischaemic heart disease, valvular heart disease